CrossrefInfokarte
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide
Clinical Pharmacokinetics · 2026-07 · 65 (7) · 1087-1099
DOI: 10.1007/s40262-026-01654-0 ↗Abstract
Kein Abstract verfügbar.
EUVIMED